Arcus Biosciences (RCUS) Accumulated Expenses (2017 - 2023)

Arcus Biosciences' Accumulated Expenses history runs 7 years deep, the most recent figure standing at $15.0 million for Q2 2023.

• On a quarterly basis, Accumulated Expenses rose 3.89% year-over-year to $15.0 million in Q2 2023; TTM through Jun 2023 was $15.0 million, a 3.89% increase from a year earlier, with the FY2022 full-year figure at $25.0 million, up 47.06% from the prior year.
• Accumulated Expenses grew to $15.0 million in Q2 2023 per RCUS's latest filing, from $12.0 million in the prior quarter.
• Across five years, Accumulated Expenses topped out at $25.0 million in Q4 2022 and bottomed at $2.0 million in Q1 2019.
• The 5-year median for Accumulated Expenses is $10.7 million (2021), against an average of $10.7 million.
• Across the five-year window, Accumulated Expenses surged 258.18% in 2019 and tumbled 74.41% in 2020, its largest moves.
• Year by year, Accumulated Expenses stood at $5.0 million in 2019, then surged by 92.79% to $9.5 million in 2020, then jumped by 78.14% to $17.0 million in 2021, then jumped by 47.06% to $25.0 million in 2022, then plunged by 40.0% to $15.0 million in 2023.
• Per Business Quant, the three latest RCUS Accumulated Expenses figures stand at $15.0 million (Q2 2023), $12.0 million (Q1 2023), and $25.0 million (Q4 2022).